Buoyed by positive response from its cord blood banking
and cord lining banking businesses, Cordlife incorporated a
Diagnostics Business Unit to continue its focus on developing
the scope of complementary offerings. The first service
launched under this unit was Metascreen, an advanced
non-invasive metabolic screening test for newborn babies.
This was first launched in India in 2013 and subsequently in
Hong Kong, the Philippines and Indonesia in 2014.
COMMITMENT TO HIGH QUALITY STANDARDS
By placing emphasis on quality, Cordlife has grown to
become a dominant private cord blood bank operator in
Singapore and is among the pioneers in Asia. Accreditation
and certification of its quality system by external quality
bodies aid in providing families and physicians with the
assurance that cord blood and cord lining units stored with
Cordlife will be processed and stored in accordance with the
highest standards.
The Group’s processing and storage facilities in Singapore,
Hong Kong and India are accredited by AABB, the world’s
gold standard in cord blood banking and its facilities in
Indonesia and the Philippines are also ISO-certified.
ACCOMPLISHMENTS
Cordlife is a trailblazer in the cord blood banking and cord
lining banking industry, having achieved several milestones
in the past years. One of them includes being the first
few cord blood banks in Singapore, Hong Kong and the
Philippines to establish a successful cord blood release
track record, which is a validation of the Group’s quality
standards. Cordlife was also the first few companies in Asia to
progress into using fully automated systems for cord blood
processing. These are just a few milestones that demonstrate
Cordlife’s commitment to deliver client-centric outcomes.
On the investor-relations front, Cordlife’s efforts have
culminated in the receipt of a Merit Award under the “Best
Investor Relations” category at the Singapore Corporate
Awards in 2013. Adding to that, Cordlife was titled the “Most
Transparent Company” in the Retail & Household Goods
and the Mainboard Small Caps Category at the 14th SIAS
Investors’ Choice Awards in 2013.
From the business aspect, Cordlife was selected out of
17,000 companies in Asia as one of the Best “Under A Billion”
companies by Forbes Asia in 2015. Other recent accolades
awarded to Cordlife by the industry comprise the “Baby &
Kid Brands Awards” 2013, “My Favourite Cord Blood Bank”
by Hong Kong Economic Times; 2014 “Most Popular Stem
Cell Bank Reader’s Choice” by Child Magazine; 2013-2014
“MyBB Parent-Child Favorite Cord Blood and Umbilical Cord
Bank Company”, 2015 “Most Popular Stem Cell Bank Reader’s
Choice” by Child Magazine; and 2014-2015 “MyBB Parent-
Child Favorite Cord Blood”.
5
CORDLIFE GROUP LIMITED
| ANNUAL REPORT 2015
CORPORATE
PROFILE
